Restoring PU.1 induces apoptosis and modulates viral transactivation via interferon-stimulated genes in primary effusion lymphoma

• Published in: Oncogene 2017-09, Vol.36 (37), p.5252-5262
• Main Authors: Goto, H, Kariya, R, Kudo, E, Okuno, Y, Ueda, K, Katano, H, Okada, S
• Format: Article
• Language: English
• Subjects: 13/106; 13/51; 38/77; 42/109; 631/326/596; 631/67/1990/291/1621/1915; 631/80/82/23; 82/80; Animal models; Animals; Apoptosis; Apoptosis - physiology; Ascites; B-cell lymphoma; Care and treatment; Cell Biology; Cell Line, Tumor; Cell Proliferation - physiology; Chromatin; Complications and side effects; Demethylation; Development and progression; DNA Methylation; DNA microarrays; Effusion; Genetic aspects; Health aspects; Herpes; Herpes viruses; Herpesvirus diseases; Heterografts; Human Genetics; Humans; Immunoprecipitation; Interferon; Interferon regulatory factor 7; Interferon Regulatory Factor-7 - biosynthesis; Interferon Regulatory Factor-7 - genetics; Interferons - genetics; Interferons - pharmacology; Internal Medicine; Lymphocytes B; Lymphoma; Lymphoma, Primary Effusion - genetics; Lymphoma, Primary Effusion - metabolism; Lymphoma, Primary Effusion - pathology; Male; Medicine; Medicine & Public Health; Metastases; Mice; Mice, Inbred NOD; Microarray Analysis; mRNA; Non-Hodgkin's lymphomas; Oncology; original-article; Primary effusion lymphoma; Promoter Regions, Genetic; Promoters; Proto-Oncogene Proteins - genetics; Proto-Oncogene Proteins - metabolism; PU.1 protein; Regulatory sequences; Sarcoma; Trans-Activators - genetics; Trans-Activators - metabolism; Transcription factors; Transcriptional Activation; Transfection; Tumor suppression; Tumors; Xenografts
• ISSN: 0950-9232; 1476-5594
• DOI: 10.1038/onc.2017.138

Primary effusion lymphoma (PEL), which is an aggressive subgroup of B-cell lymphoma associated with Kaposi sarcoma-associated herpes virus/human herpes virus-8, is refractory to the standard treatment, and exhibits a poor survival. Although PU.1 is downregulated in PEL, the potential role of its reduction remains to be elucidated. In this investigation, we analyzed the DNA methylation of PU.1 cis -regulatory elements in PEL and the effect of restoring PU.1 on PEL cells. The mRNA level of PU.1 was downregulated in PEL cells. The methylated promoter and enhancer regions of the PU.1 gene were detected in PEL cells. Suppression of cell growth and apoptosis were caused by the restoration of PU.1 in PEL cells. A microarray analysis revealed that interferon-stimulated genes (ISGs) including pro-apoptotic ISGs were strongly increased in BCBL-1 cells after the induction of PU.1. Reporter assays showed that PU.1 transactivated pro-apoptotic ISG promoters, such as the XAF1 , OAS1 and TRAIL promoters. Mutations at the PU.1 binding sequences suppressed its transactivation. We confirmed the binding of PU.1 to the XAF1 , OAS1 and TRAIL promoters in a chromatin immunoprecipitation assay. PU.1 suppressed ORF57 activation by inducing IRF7. The reinduction of PU.1 reduced formation of ascites and lymphoma cell infiltration of distant organs in PEL xenograft model mice. Collectively, PU.1 has a role in tumor suppression in PEL and its down-regulation is associated with PEL development. Restoring PU.1 with demethylation agents may be a novel therapeutic approach for PEL.